肝癌免疫治疗及生物标志物研究进展

摘要/Abstract

摘要： 2015年我国肝癌发病率位居全部恶性肿瘤发病的第4位,死亡率居第2位。约85%的中国患者就诊时已处于中、晚期,总体5年生存率仅为12%,预后较差。2007年以来,晚期肝癌一、二线治疗以靶向治疗为主,疗效有限。近年来,以免疫检查点抑制剂为主的免疫治疗在一、二线单药治疗中分别取得了17% ~ 20%和15% ~ 20%的客观缓解率,与靶向药物以及免疫治疗等联合治疗在晚期肝癌更是表现出优于传统靶向治疗的明确抗肿瘤活性。免疫治疗在肝癌新辅助及辅助治疗领域也取得了初步成果,但面临着诸如治疗后疾病进展以及肝移植复发后方案选择等现实挑战。寻找免疫特异性生物标志物成为肝癌免疫治疗领域的重要方向。本文就肝癌免疫治疗及生物标志物的研究进展展开综述。

关键词: 肝细胞癌, 免疫治疗, 生物标志物

Abstract: The incidence of hepatocellular carcinoma (HCC) in China ranked fourth among all malignant tumors, and the mortality rate ranked second in 2015. Approximately 85% of Chinese patients are in the intermediate stage or advanced stage at the first visit and lose the best treatment chance. The 5-year survival rate of them is only 12%. Since 2007, treatments for advanced hepatocellular carcinoma mostly focused on targeted therapy, with limited efficacy. In recent years, immune checkpoint inhibitors have achieved 17% ~ 20% and 15% ~ 20% objective response rate in first-line and second-line monotherapy respectively. Immunotherapy shows obviously anti-tumor effect that is superior to traditional targeted therapy. Initial results have also achieved in the field of neoadjuvant and adjuvant therapy for HCC. However, several challenges such as treatment selection after disease progression and disease recurrence after liver transplantation are still unsolved. Exploring immune-specific biomarkers to predict the efficacy has also become an important direction in the field of immunotherapy. In this review, we summarized the research progress of immunotherapy and biomarkers for hepatocellular carcinoma.

Key words: Hepatocellular carcinoma, Immunotherapy, Biomarkers

彭雪楠, 周爱萍. 肝癌免疫治疗及生物标志物研究进展[J]. 肝癌电子杂志, 2020, 7(4): 17-22.

Peng Xuenan, Zhou Aiping. Research progress in immunotherapy and biomarkers for hepatocellular carcinoma[J]. Electronic Journal of Liver Tumor, 2020, 7(4): 17-22.

参考文献

[1] LLOVET J M, ZUCMAN-ROSSI J, PIKARSKY E, et al.Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2016, 14(2):16018.
[2] BRAY F, FERLAY J, SOERJOMATARAM I, et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
[3] 安澜, 曾红梅, 郑荣寿, 等. 2015年中国肝癌流行情况分析[J]. 中华肿瘤杂志, 2019, 41(10):721-727.
[4] European Association for the Study of the Liver. EASL Clinical Practice Guidelines:Management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1):182-236.
[5] QIN SK, CHENG Y, LIANG J, et al.Efficacy and Safety of the FOLFOX4 Regimen Versus Doxorubicin in Chinese Patients With Advanced Hepatocellular Carcinoma:A Subgroup Analysis of the EACH Study[J]. Oncologist, 2014, 19(11):1169-1178.
[6] CHENG AL, KANG YK, CHEN ZD, et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10(1):25-34.
[7] LLOVET J M, RICCI S, MAZZAFERRO V, et al.Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(4):378-390.
[8] KUDO M, FINN R S, QIN SK, et al.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma:a randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126):1163-1173.
[9] BRUIX J, QIN SK, MERLE P, et al.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment(RESORCE):a randomised, double-blind, placebo-controlled, phase 3 trial[J].Lancet, 2017, 389(10064):56-66.
[10] ABOU-ALFA G K, MEYER T, CHENG AL, et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma[J]. N Engl J Med, 2018, 379(1):54-63.
[11] ZHU A X, KANG Y K, YEN C J, et al.Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations(REACH-2):a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2019, 20(2):282-296.
[12] BISHOP G A, BERTOLINO P D, BOWEN D G, et al.Tolerance in liver transplantation[J]. Best Pract Res Clin Gastroenterol, 2012, 26(1):73-84.
[13] SHI F, SHI M, ZENG Z, et al.PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients[J]. Int J Cancer, 2011, 128(4):887-896.
[14] KUREBAYASHI Y, OJIMA H, TSUJIKAWA H, et al.Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification[J]. Hepatology, 2018, 68(3):1025-1041.
[15] MELLMAN I, COUKOS G, Dranoff G.Cancer immunotherapy comes of age[J]. Nature, 2011, 480(7378):480-489.
[16] PARRY R V, CHEMNITZ J M, FRAUWIRTH K A, et al.CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms[J]. Mol Cell Biol, 2005, 25(21):9543-9553.
[17] FUKUMURA D, KLOEPPER J, AMOOZGAR Z, et al.Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges[J]. Nat Rev Clin Oncol, 2018, 15(5):325-340.
[18] CHEN D S, IRVING B A, HODI F S.Molecular Pathways:Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1[J]. Clin Cancer Res, 2012, 18(24):6580-6587.
[19] TABCHI S, MESSIER C, BLAIS N.Immune-mediated respiratory adverse events of checkpoint inhibitors[J]. Curr Opin Oncol, 2016, 28(4):269-277.
[20] EL-KHOUEIRY A B, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma(CheckMate 040):an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088):2492-2502.
[21] SANGRO B, PARK J W, DELA CRUZ C M, et al. A randomized, multicenter, phase 3 study of nivolumab vs sorafenib as first-line treatment in patients(pts) with advanced hepatocellular carcinoma(HCC):CheckMate-459[J]. J Clin Oncol, 2016, 34(15 suppl):TPS4147-TPS4147.
[22] LEE M S, RYOO BY, HSU CH, et al.Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma(GO30140):an open-label, multicentre, phase 1b study[J]. Lancet Oncol, 2020, 21(6):808-820.
[23] GALLE P R, FINN R S, QIN SK, et al.Patient-reported outcomes(PROs) from the Phase III IMbrave150 trial of atezolizumab(atezo) + bevacizumab(bev) vs sorafenib(sor) as first-line treatment(tx) for patients(pts) with unresectable hepatocellular carcinoma(HCC)[J]. J Clin Oncol, 2020, 38(4 suppl): 476-476.
[24] FINN R S, QIN SK, IKEDA M, et al.Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma[J]. N Engl J Med, 2020, 382(20):1894-1905.
[25] IKEDA M, SUNG M W, KUDO M, et al.A phase 1b trial of lenvatinib(LEN) plus pembrolizumab(PEM) in patients(pts) with unresectable hepatocellular carcinoma(uHCC)[J]. J Clin Oncol, 2018, 36(15 suppl):4076-4076.
[26] LLOVET J M, KUDO M, CHENG A L, et al. Lenvatinib(len) plus pembrolizumab(pembro) for the first-line treatment of patients(pts) with advanced hepatocellular carcinoma(HCC):Phase 3 LEAP-002 study[J]. J Clin Oncol, 2019, 37(15 suppl):TPS4152-TPS4152.
[27] ZHANG W. Preliminary results of sintilimab plus different dose of IBI305(anti-VEGF monoclonal antibody) in patients with advanced hepatocellular carcinoma:A phase Ib study, ASCO Virtual Scientific Program, F, 2020[C]. American Society of Clinical Oncology.
[28] KELLEY R K, SANGRO B, HARRIS W P, et al.Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab(T) in combination with durvalumab(D) for patients(pts) with advanced hepatocellular carcinoma(aHCC)[J]. J Clin Oncol, 2020, 38(15 suppl):4508-4508.
[29] QIN S, CHEN Z, LIU Y, et al.A phase II study of anti-PD-1 antibody camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy as first-line therapy for advanced hepatocellular carcinoma or biliary tract cancer[J]. J Clin Oncol, 2019, 37(15 suppl):4074-4074.
[30] ZHU A X, FINN R S, EDELINE J, et al.Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib(KEYNOTE-224):a non-randomised, open-label phase 2 trial[J]. Lancet Oncol, 2018, 19(7):940-952.
[31] FINN R S, RYOO B-Y, MERLE P, et al.Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240:A Randomized, Double-Blind, Phase III Trial[J]. J Clin Oncol, 2020, 38(3):193-202.
[32] QIN S K, REN Z G, MENG Z Q, et al. A randomized multicenter phase 2 study to evaluate SHR-1210(PD-1 Antibody) in subjects with advanced hepatocellular carcinoma(HCC) who failed or were intolerant to prior systemic treatment[C].2018, ESMO:LBA27:1-16.
[33] WANG F, QIN S K, SUN X C, et al.Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab:data derived from a multicenter phase 2 trial[J]. J Hemato Oncol, 2020, 13(1):47.
[34] XU J M, ZHANG Y, JIA R, et al.Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer:An Open-label, Dose Escalation and Expansion Study[J]. Clin Cancer Res. 2019, 25(2):515-523.
[35] XU J, SHEN J, GU S, et al. Camrelizumab(C) in combination with apatinib(A) in patients with advanced hepatocellular carcinoma (RESCUE): An open-label, multi-center, phase II trial[J]. Clin Cancer Res, 2020:clincanres.2571.2020.
[36] YAU T, KANG YK, KIM TY, et al.Nivolumab(NIVO) + ipilimumab(IPI) combination therapy in patients(pts) with advanced hepatocellular carcinoma(aHCC):Results from CheckMate 040[J]. J Clin Oncol, 2019, 37(15 suppl):4012-4012.
[37] SPOSITO C, MARIANI L, GERMINI A, et al.Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation:A case-control study[J]. J Hepatol, 2013, 59(1):59-66.
[38] PFEIFFENBERGER J, KOSCHNY R, HOFFMANN K, et al.Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation[J]. Langenbecks Arch Surg, 2013, 398(8):1123-1128.
[39] AU P K, HO CHOK K S. Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma:A proposed management algorithm[J]. World J Gastroenterol, 2018, 24(45):5081-5094.
[40] VARKARIS A, LEWIS D W, NUGENT F W.Preserved Liver Transplant After PD-1 Pathway Inhibitor for Hepatocellular Carcinoma[J]. Am J Gastroenterol, 2017, 112(12):1895-1896.
[41] DE TONI E N, GERBES A L. Tapering of Immunosuppression and Sustained Treatment With Nivolumab in a Liver Transplant Recipient[J]. Gastroenterology, 2017, 152(6):1631-1633.
[42] FRIEND B D, VENICK R S, MCDIARMID S V, et al.Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma[J]. Pediatr Blood Cancer, 2017, 64(12) .
[43] RAMMOHAN A, REDDY M S, FAROUK M, et al.Pembrolizumab for metastatic hepatocellular carcinoma following live donor liver transplantation: The silver bullet[J]? Hepatology, 2018, 67(3):1166-1168.
[44] KASEB A O, CAO H S T, MOHAMED Y I, et al. Final results of a randomized, open label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC[J]. J Clin Oncol, 2020, 38(15 suppl):4599-4599.
[45] SUN H-C, ZHU X-D, HUANG C, et al.Initially unresectable hepatocellular carcinoma treated by combination therapy of tyrosine kinase inhibitor and anti-PD-1 antibody followed by resection[J]. J Clin Oncol, 2020, 38(15 suppl):e16690.
[46] PINATO D J, COLE T, BENGSCH B, et al.A phase Ib study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma(HCC):PETAL[J]. Ann Oncol, 2019, 30(5 suppl):v253-v324.
[47] OGASAWARA S, LLOVET J, EL-KHOUEIRY A, et al.LEAP-012:A randomized, double-blind, phase 3 study of pembrolizumab plus lenvatinib in combination with transarterial chemoembolization(TACE) in patients with intermediate-stage hepatocellular carcinoma not amenable to curative treatment[J]. Ann Oncol, 2020.
[48] SANGRO B, KUDO M, QIN S, et al.A phase 3, randomized, double-blind, placebo-controlled study of transarterial chemoembolization combined with durvalumab or durvalumab plus bevacizumab therapy in patients with locoregional hepatocellular carcinoma:EMERALD-1[J]. Ann Oncol, 2020.
[49] DHARMAPURI S, ÖZBEK U, LIN J Y, et al.Predictive value of neutrophil-lymphocyte ratio(NLR) and platelet-lymphocyte ratio(PLR) In hepatocellular carcinoma(HCC) patients treated with nivolumab(N)[J]. Ann Oncol, 2019, 30:v285-v286.
[50] LOSIC B, CRAIG A J, VILLACORTA-MARTIN C, et al.Intratumoral heterogeneity and clonal evolution in liver cancer[J]. Nat Commun, 2020, 11(1):291.
[51] HUANG M L, HE M H, GUO Y, et al.The Influence of Immune Heterogeneity on the Effectiveness of Immune Checkpoint Inhibitors in Multifocal Hepatocellular Carcinomas[J]. Clin Cancer Res, 2020, 26(18):4947-4957.
[52] BERRAONDO P, OCHOA M C, OLIVERA I, et al.Immune Desertic Landscapes in Hepatocellular Carcinoma Shaped by β-Catenin Activation[J]. Cancer Discovery, 2019, 9(8):1003-1005.
[53] SIA D, JIAO Y, MARTINEZ-QUETGLAS I, et al.Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features[J]. Gastroenterology, 2017, 153(3):812-826.
[54] HARDING J J, NANDAKUMAR S, ARMENIA J, et al.Prospective Genotyping of Hepatocellular Carcinoma:Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies[J]. Clin Cancer Res, 2019, 25(7):2116-2126.